Full-Time
Registered Nurse Case Manager
Hospice
BrightSpring Health Services
10,001+ employees
Home-based and community health services, pharmacy
No salary listed
Williamsburg, VA, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
- Graduate of an accredited nursing school with current licensure to practice in state of operation
- One year nursing experience required, 3+ years preferred
- Knowledge of the hospice philosophy of care
- Commitment to clinical and documentation excellence
- Must be a licensed driver with an automobile that is insured in accordance with state/or organization requirements and is in good working order
- Assess/monitor physical, emotional, and psychological needs of patients
- Create hospice care plans that align with the patients wishes and goals
- Direct nursing care: administering medications, treatments, and interventions
- Provide pain and symptom management
- Educate and support the patient’s family and caregivers
- Collaborate with interdisciplinary team
- Maintain accurate and timely documentation
- Participate in on-call rotation as required by local branch
- Experience in hospice or a similar setting preferred
- 3+ years nursing experience preferred
- Knowledge of hospice philosophy of care
BrightSpring Health Services provides home and community-based health care through two main operations: Pharmacy and Provider. In Pharmacy, it offers services for patients with complex and chronic conditions, including specialty, infusion, and community pharmacy solutions. In Provider, it delivers home health, behavioral health, hospice care, and services for intellectual and developmental disabilities. The company uses an integrated care model that connects pharmacy services with in-home care across its network to support patients, families, and managed care organizations. Revenue comes from reimbursed services paid by Medicare, Medicaid, and private insurers. Its goal is to coordinate ongoing, in-home and community-based care across a continuum—from pharmacy support to direct care—ensuring coordinated, patient-centered services for individuals with complex or chronic needs.
Company Size
10,001+
Company Stage
Post IPO Equity
Headquarters
Louisville, Kentucky
Founded
1974
Simplify's Take
What believers are saying
- Specialty and infusion revenue grew 35.5% year over year in Q1 2026.
- Amedisys and LHC integrations add about $30 million EBITDA in year one.
- Community living divestiture freed $811 million cash for higher-growth core services.
What critics are saying
- Medicare Part D cuts and brand-to-generic pressure create about $600 million headwinds.
- Home health acquisitions still require integration; clinician turnover would quickly erode margins.
- Government reimbursement and compliance exposure can hit pharmacy, hospice, and home health simultaneously.
What makes BrightSpring Health Services unique
- Integrated pharmacy and provider services target complex, chronic-care patients across home settings.
- National footprint spans behavioral health, home health, hospice, and intellectual disability services.
- Limited distribution drugs and specialty infusion deepen pharmacy differentiation and patient retention.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at BrightSpring Health Services who can refer or advise you
Benefits
Flexible Work Hours
Company News
BrightSpring Health Services announced the resignation of Robert Barnes as President of ResCare Community Living on 30 March 2026, stating it was not due to any disagreement over operations or policies. The company's shares rose 5.2% following upbeat analyst reports from its investor day. Management unveiled ambitious long-term organic EBITDA growth targets of 15% to 20% annually through 2028, alongside AI-driven efficiency plans for its home and community-based care platform. The narrative projects $16.8 billion in revenue and $361.8 million in earnings by 2028, requiring 10.1% yearly revenue growth. Investors remain focused on whether BrightSpring can balance acquisition-driven expansion and technology investment whilst managing its substantial debt load and regulatory exposure.
BrightSpring Health Services has seen its stock price surge 43.1% over the past six months to $42.32 per share, driven by strong quarterly results. The healthcare services company, founded in 1974, offers home health care, hospice, neuro-rehabilitation and pharmacy services. BrightSpring's revenue grew at an 18.3% compound annual growth rate over the past five years, outpacing the healthcare sector average. Analysts forecast 15% revenue growth over the next 12 months, though this represents a deceleration from its recent 20.9% annual rate. However, the company's five-year average return on invested capital of 4.9% falls below the typical cost of capital for healthcare firms, suggesting historically mediocre capital efficiency. The stock currently trades at 27.7× forward price-to-earnings ratio.
BrightSpring Health Services has raised questions about its valuation after trading at 24.5 times forward earnings following strong 2025 performance. The company reported fourth-quarter revenue of $3.55 billion, up 29.3% year-over-year, with adjusted EBITDA rising 40.7% to $184 million. For 2026, management guided revenue between $14.45 billion and $15 billion, representing 11.9% to 16.2% growth, whilst adjusted EBITDA is expected to grow faster at 23% to 28%, indicating margin expansion. However, the company faces approximately $600 million in revenue headwinds from Inflation Reduction Act impacts and brand-to-generic conversions. The valuation hinges on whether BrightSpring can deliver sequential profitability improvements throughout the year despite policy and product-mix pressures affecting headline revenue growth.
BrightSpring Health Services led senior health stocks in Q4 earnings, reporting revenues of $3.55 billion, up 16.3% year on year and beating analyst expectations by 5%. The company delivered strong full-year EBITDA guidance. In contrast, Chemed posted the weakest performance, with revenues of $639.3 million falling 3% short of expectations. The company missed both revenue and full-year EPS guidance estimates, sending shares down 19.2% to $377.07. The seven senior health, home health and hospice stocks tracked reported slower Q4 results overall, with revenues beating consensus estimates by just 1.1%. Share prices have declined an average of 9.6% since earnings releases. The sector faces headwinds from labour shortages and wage inflation whilst benefiting from an ageing population and growing preference for in-home care.
BrightSpring Health Services outlined its growth strategy at an investor day, highlighting a shift towards core home-and-community clinical services. The company's planned community-living divestiture will close soon to boost cash flow and support integrated care initiatives. BrightSpring reported significant deleveraging from approximately 4.5x post-IPO to 2.99x (2.6x pro forma), with leverage expected to fall below 2x in 2026. The company reiterated 2026 guidance of $14.45–$15.0 billion revenue and $760–$790 million adjusted EBITDA, whilst targeting 15–20% organic adjusted EBITDA compound annual growth for 2026–2028. The healthcare services provider has at least $2 billion available for acquisitions through 2028. Its operations include dispensing over 40 million prescriptions annually through PharMerica, serving more than 4 million patients, with recent branch integrations expected to add approximately $30 million of EBITDA.